- Report
- August 2023
- 395 Pages
Global
From €3772EUR$4,200USD£3,222GBP
- Report
- June 2022
- 327 Pages
Global
From €3144EUR$3,500USD£2,685GBP
- Report
- August 2024
- 294 Pages
Global
From €3750EUR$4,175USD£3,203GBP
- Report
- February 2024
- 173 Pages
Global
From €5344EUR$5,950USD£4,565GBP
- Report
- August 2025
- 182 Pages
Global
From €3184EUR$3,545USD£2,720GBP
€3538EUR$3,939USD£3,022GBP
- Report
- August 2025
- 185 Pages
Global
From €3184EUR$3,545USD£2,720GBP
€3538EUR$3,939USD£3,022GBP
- Report
- August 2025
- 196 Pages
Global
From €3184EUR$3,545USD£2,720GBP
€3538EUR$3,939USD£3,022GBP
- Report
- August 2025
- 196 Pages
Global
From €3184EUR$3,545USD£2,720GBP
€3538EUR$3,939USD£3,022GBP
- Report
- August 2025
- 181 Pages
Global
From €3184EUR$3,545USD£2,720GBP
€3538EUR$3,939USD£3,022GBP
- Report
- August 2025
- 190 Pages
Global
From €3184EUR$3,545USD£2,720GBP
€3538EUR$3,939USD£3,022GBP
- Report
- August 2025
- 194 Pages
Global
From €3184EUR$3,545USD£2,720GBP
€3538EUR$3,939USD£3,022GBP
- Report
- August 2025
- 180 Pages
Global
From €3184EUR$3,545USD£2,720GBP
€3538EUR$3,939USD£3,022GBP
- Report
- August 2025
- 188 Pages
Global
From €3184EUR$3,545USD£2,720GBP
€3538EUR$3,939USD£3,022GBP
- Report
- August 2025
- 181 Pages
Global
From €3184EUR$3,545USD£2,720GBP
€3538EUR$3,939USD£3,022GBP
- Report
- August 2025
- 185 Pages
Global
From €3184EUR$3,545USD£2,720GBP
€3538EUR$3,939USD£3,022GBP
- Report
- July 2025
- 200 Pages
Mexico
From €2236EUR$2,490USD£1,910GBP
- Report
- December 2023
- 153 Pages
Global
From €2223EUR$2,475USD£1,899GBP
€4446EUR$4,950USD£3,798GBP
- Report
- November 2021
- 256 Pages
Global
From €2358EUR$2,625USD£2,014GBP
€4715EUR$5,250USD£4,028GBP
- Report
- March 2025
- 120 Pages
Global
From €5344EUR$5,950USD£4,565GBP
- Report
- June 2025
- 120 Pages
Global
From €5344EUR$5,950USD£4,565GBP

Single Use Bioreactors (SUBs) are bioreactors that are designed for a single use and then disposed of. They are used in biotechnology for the production of biopharmaceuticals, such as vaccines, monoclonal antibodies, and recombinant proteins. SUBs are typically made of plastic and are pre-sterilized, eliminating the need for cleaning and sterilization between batches. This makes them ideal for rapid scale-up and production of biopharmaceuticals. SUBs also offer advantages such as reduced risk of contamination, improved process control, and reduced capital costs.
The SUB market is growing rapidly due to the increasing demand for biopharmaceuticals and the need for rapid scale-up and production. SUBs are becoming increasingly popular in the biotechnology industry due to their cost-effectiveness and convenience.
Some companies in the SUB market include Sartorius, Thermo Fisher Scientific, Merck KGaA, GE Healthcare, and Pall Corporation. Show Less Read more